No Detail Found!

Intravitreal Bevacizumab (IVB) for Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO).

Author(s)
Muhammad Naeem Azhar Department of Vitreo Retina, Armed Forces Institute of Ophthalmology (AFIO), Rawalpindi, Pakistan
Waqar Muzaffar Department of Vitreo Retina, Armed Forces Institute of Ophthalmology (AFIO), Rawalpindi, Pakistan
Muhammad Aamir Arain Department of Vitreo Retina, Armed Forces Institute of Ophthalmology (AFIO), Rawalpindi, Pakistan
Omer Farooq Department of Vitreo Retina, Armed Forces Institute of Ophthalmology (AFIO), Rawalpindi, Pakistan
Abstract
Objective: To evaluate the effectiveness of intravitreal Bevacizumab in decreasing central macular thickness in branch retinal vein occlusion (BRVO) related macular edema. Study Design: Quasi experimental study. Place and Duration of Study: Armed Forces Institute of Ophthalmology (AFIO), Rawalpindi, Pakistan, from March to August 2017. Methodology: Intravitreal Bevacizumab (1.25 mg/0.05 ml) was given in inferotemporal quadrant under aseptic conditions on monthly basis for consective three months. Post-injection, all the patients were followed up on monthly basis for consecutive three months. CMT (in µm) was measured by using OCT at baseline and after intravitreal Bevacizumab injections at one month, two months, and finally at three months. Results: Forty eyes of forty patients were included in the study. There were 25 (62.5%) male patients and 15 (37.5%) female patients. Baseline mean CMT ±SD was 358 ±36 µm before IVB injection. Mean CMT was 252 ±12 µm at 3 months (after three IVB injections). At three months, mean percentage decrease in CMT was 29.60%. Conclusion: Intravitreal Bevacizumab is effective and results in decrease in central macular thickness to normal or nearnormal levels in branch retinal vein occlusion (BRVO) related macular edema.
Publication Details
Page(s) 758-761
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 28, Issue: 10, Year: 2018

Request the full text from PASTIC

References
JaulimA,AhmedB,KhanamT,ChatziralliIP, 2013.Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature,Retina 33 901 -91
HahnP,FekratS., 2012.Best practices for treatment of retinal vein occlusion,Curr Opin Ophthalmol 23 175 -81
KolarP, 2014.Risk factors for central and branch retinal vein occlusion: A meta-analysis of published clinical data,J Ophthalmol 724 -80
SchachatAP,WilkinsonCP,HintonDR,SaddaSR,WicdermannP, 2018.Branch retinal vein occlusion,In: Ryan's Retina, ed. 6th. Elsevier 1155 -65
TanMH,McAllisterIL,GilliesME,VermaN,BanerjeeG, 2014.Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion,Am J Ophthalmol 157 237 -47
LeeWJ,KangMH,SeongM,ChoHY, 2012.Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinalvein occlusion,Br J Ophthalmol 96 1426 -30
NomaH,FunatsuH,YamasakiM., 2008.Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular edema in branch retinal vein occlusion,Graefes Arch Clin Exp Ophthalmol 244 309 -15
HikichiT,HiguchiM,MatsushitaT, 2014.Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion,Br J Ophthalmol 98 195 -9
DonatiS,BaroslP,BianchiM., 2012.Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion,Eur J Ophthalmol 22 607 -14
GabrieleML,WollsteinG,IshikawaH, 2011.Optical coherence tomography: history, current status, and laboratory work,Invest Ophthalmol Vis Sci 52 2425 -36
SpaideRF,LeeJK,KlancnikJK, 2003.Optical coherence tomography of branch retinal vein occlusion,Retina 23 343 -7
MitchellP,SmithW,ChangA, 1996.Prevalence and associations of retinal vein occlusion in Australia. The blue mountains eye study,Arch Ophthalmol 114 1243 -7
KumagaiK., 2014.Three-dimensional optical coherence tomography evaluation of vascular changes at arteriovenous crossings,Retina 55 1867 -75
BatesDO, 2010.Vascular endothelial growth factors and vascular permeability,Cardiovasc Res 87 262 -87
ParkSP,AhnJK, 2009.Changes of aqueous vascular endothelial growth factor and pigment epithelium-derived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion,Clin Exp Ophthalmol 37 490 -5
JaislleGB,LeitritzM, 2009.One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion,Graefes Arch Clin Exp Ophthalmol 247 27 -33
KornhauserT,SchwartzR,GoldsteinM,NeudorferM,LoewensteinA,BarakA, 2016.Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up),Graefes Arch Clin Exp Ophthalmol 254 835 -44
WuL,ArevaloJF,BerrocalMH, 2009.Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months,Retina 29 1396 -403
AhnSJ,AhnJ,WooSJ,ParkKH, 2013.Initial dose of three monthly intravitreal injections versus PRN intravitreal injections of bevacizumab for macular edema secondary to branch retinal vein occlusion,BioMed Res Int 209735 -
PaiSA,ShettyR,VijayanPB, 2007.Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion,Am J Ophthalmol 143 601 -6
NoritatasuY,AkitakaT,AtsushiS., 2009.Retinal sensitivity after intravitreal injection of bevacizumab for the treatment of macular edema secondary to retinal vein occlusion,Retina 29 757 -67
SherifE., 2008.Intravitreal bevacizumab treatment for macular edema secondary to central and branch retinal vein occlusion,J Egypt Ophthalmol Soc 1 73 -8
0

Citations

0

Downloads

60

Views